Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Shrager

Dermatology Sellersville, PA Medical Doctor

NPI 1396784120 CMS profile 244953

670 Lawn Ave, Suite 1A, Sellersville, PA 18960

Open in the dashboard

General payments

$25,695

1,724 records reported · program years 2019–2025

Research payments

$1,884

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$32,803 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Daniel Shrager of Sellersville, PA is reported in the CMS Open Payments database as having received $25,695 across 1,724 general payments and $1,884 in research payments paid to them. Separately, studies naming them as principal investigator received $32,803 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 90th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,553 260
2024 General $4,492 282
2023 General $3,816 241
2022 General $3,699 279
2021 General $3,545 285
2020 General $2,865 199
2020 Research $1,884 3
2019 General $2,724 178

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Shrager
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Daniel Shrager were reported at $4,553. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Daniel Shrager Dermatology median Middle half National median
2019 $2,724 $454 $129–$1,240 $163
2020 $2,865 $235 $81–$756 $114
2021 $3,545 $377 $108–$1,108 $132
2022 $3,699 $514 $143–$1,391 $149
2023 $3,816 $607 $159–$1,674 $160
2024 $4,492 $751 $204–$1,903 $164
2025 $4,553 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,708 296 payments
  2. Janssen Biotech, Inc. $3,091 237 payments
  3. Sun Pharmaceutical Industries Inc. $1,801 86 payments
  4. Galderma Laboratories, L.P. $1,571 151 payments
  5. Organogenesis Inc. $1,356 55 payments
  6. VYNE Pharmaceuticals Inc. $1,289 101 payments
  7. UCB, Inc. $1,213 73 payments
  8. Lilly USA, LLC $1,079 74 payments
  9. E.R. Squibb & Sons, L.L.C. $1,061 78 payments
  10. Pfizer Inc. $1,026 72 payments
  11. Other $8,500 501 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $24,874 1,713 payments
  2. Education $821 11 payments
Products named General payments · program years 2019–2025
  1. TREMFYA $3,159 237 payments
  2. RINVOQ $1,984 153 payments
  3. DUPIXENT $1,126 42 payments
  4. SOTYKTU $1,060 77 payments
  5. SKYRIZI $1,045 93 payments
  6. AMZEEQ $988 75 payments
  7. TALTZ $954 65 payments
  8. ILUMYA $840 47 payments
  9. CIBINQO $787 57 payments
  10. EUCRISA $744 51 payments
  11. Other $16,712 1,086 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Regeneron Pharmaceuticals, Inc. $1,884 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

749

Median for Dermatology: 534

Drug cost

$245,255

Median for Dermatology: $67,151

Branded share of claims

13%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 46 $169,335
Cibinqo Abrocitinib Brand 16 $53,999
Clobetasol Propionate Generic 130 $7,186
Doxycycline Hyclate Generic 79 $3,742
Triamcinolone Acetonide Generic 175 $3,234
Ivermectin Generic 16 $2,565
Tretinoin Generic 13 $1,152
Imiquimod Generic 37 $944
Valacyclovir Valacyclovir Hcl Brand 35 $855
Ketoconazole Generic 49 $613

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 106 billing codes

Paid by Medicare

$4,125,057

Of which drugs: $2,309,061

Medicare patients

2,079

Average age 74

Services billed

40,944

1,052 women, 1,027 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 42%
Ischemic heart disease 22%
Diabetes 20%
Chronic kidney disease 20%
Atrial fibrillation 17%
Depression 17%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, tildrakizumab, 1 mg J3245 Office 49 18,400 $1,979,485
Novachor, per square centimeter Q4194 Office 19 265 $212,005
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 27 48 $36

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 31 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$448 — —
SOTYKTU
$416 — —
RINVOQ
$399 — —
DUPIXENT
$339 46 —
SKYRIZI
$279 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 31 with Patron

Records

1,727 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record